KABONIB(Cabozantinib )
Therapeutic class: Kinase Inhibitors
- Advanced Renal Cell Carcinoma (RCC)
- Advanced Renal Cell Carcinoma, as a first-line treatment in combination with nivolumab
- Hepatocellular Carcinoma (HCC) who have been previously treated with sorafenib
20mg & 40mg & 60 mg Tablets
20mg:-
A bottle of 30 tablets40 mg:-
A bottle of 30 tablets60 mg:-
A bottle of 30 tablets- 20°C to 25°C (68°F to 77°F), Shelf Life: 2 Years
- As directed by physician
